The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

Viatris

Status and phase: Completed; Phase 3

Conditions: Pulmonary Hypertension

Treatments: Drug: Sildenafil citrate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00159861

A1481141

Details and patient eligibility

About

Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension

Enrollment: 267 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with pulmonary arterial hypertension caused by primary PAH, associated with connective tissue disease or following surgical repair of a congenital heart lesion

Exclusion criteria

• PH other than PAH

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind